Ryvu Therapeutics S.A. — Sponsor Intelligence | 6 EU Trials

Filter these 6 trials by condition, phase, country and more.

6 Registered trials

4 Recruiting

2 Completed trials

4 Countries active

6 Unique IMPs

100% Results reported

Phase II

Oversight events:

3 urgent safety measures across 3 trials

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

Top indications

6 total

RVU120 Rollover Study Recruiting

2025-521673-14-00 Phase II 4 countries 7,8-DIBROMO-5,6-DIHYDRO-9-METHYL-2-(1-PIPERAZINYL)-4H-IMIDAZO[4,5,1-IJ]QUINOLINE…
Study of MEN1703 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Recruiting

2024-513098-31-00 Phase II 3 countries 5,6-DIBROMO-4-NITRO-2-PIPERIDIN-4-YL-1-PROPAN-2-YLBENZIMIDAZOLE; GLOFITAMAB; OBI…
Clinical trial testing an investigational drug RVU120 for myelofibrosis (myeloproliferative neoplasm, MPN) Recruiting

2024-511688-27-00 Phase II 2 countries 7,8-DIBROMO-5,6-DIHYDRO-9-METHYL-2-(1-PIPERAZINYL)-4H-IMIDAZO[4,5,1-IJ]QUINOLINE…
A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of RV… Recruiting

2023-505911-19-00 Phase II 4 countries 7,8-DIBROMO-5,6-DIHYDRO-9-METHYL-2-(1-PIPERAZINYL)-4H-IMIDAZO[4,5,1-IJ]QUINOLINE…
A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myelo… Ended

2023-505910-10-00 Phase II 4 countries 7,8-DIBROMO-5,6-DIHYDRO-9-METHYL-2-(1-PIPERAZINYL)-4H-IMIDAZO[4,5,1-IJ]QUINOLINE…
RVU 120 (SEL120) to be tested in for treatment patients with solid tumors who have failed previous available standard therapy Ended

2024-515131-30-00 Phase II 2 countries 7,8-DIBROMO-5,6-DIHYDRO-9-METHYL-2-(1-PIPERAZINYL)-4H-IMIDAZO[4,5,1-IJ]QUINOLINE…

Showing 1–6 of 6 trials